入选标准

以下全部项:

• 男性或女性年龄 > 18 岁
• 自发性（非创伤性）脑出血（ICH）导致的症状性卒中，具有以下所有特征:
  • 患者/见证人否认症状发作前存在头部外伤史（可以接受ICH症状发作后出现头部外伤）
  • 脑影像（CT或MRI）符合自发性ICH表现（可能伴有继发的脑/骨/软组织损伤表现）
  • 判定为原发性脑出血（研究者认为不存在或影像学未检测出潜在结构病变）
  • ICH症状出现的时间超过24小时
    • The optimal timing for starting vs avoiding antiplatelet therapy after ICH onset is uncertain.
    • We trust that clinicians will exercise their clinical judgement and only randomise those patients in ASPIRING for whom the clinician has clinical equipoise about the potential benefits and risks of starting vs avoiding antiplatelet therapy.
    • For some clinicians and patients, there may not be equipoise until the patient has survived several weeks after ICH (e.g. a large lobar haemorrhage of uncertain cause), whereas for other clinicians and patients there may be equipoise for patients who have only recently experienced an ICH (e.g. a small putaminal haemorrhage due to hypertensive small vessel disease [normal CT angiogram] in a patient with risk factors for ischaemic vascular events and with good control of blood pressure).
    • We have elected to have wide entry criteria regarding the range of time after onset of ICH for qualifying for randomisation in ASPIRING in order to capture a wide range of patients with ICH (of variable duration since ICH onset), so that we can determine whether time since ICH onset is a significant modifier of the effect of starting vs avoiding antiplatelet therapy.
• 医生不确定是否开始或避免抗血小板治疗
• 获得知情同意